Input your search keywords and press Enter.

Saudi Arabia: Corona vaccine will cover 70% of Kingdom for free

We hope that the Corona virus vaccines will cover 70% of the Kingdom’s population by the end of 2021, Saudi Minister of Health announced, on Monday, that the Corona vaccine will be available to all citizens and residents in Saudi Arabia for free.

Saudi Minister of health said, “We hope that the Coronavirus vaccines will cover 70% of the Kingdom’s population by the end of 2021.

In addition, the Kingdom continues to record a decrease in the number of daily Covid-19 infections, as it announced today 231 new infections and 445 recovery cases, bringing the total number of recovered cases to (343,816) cases.

Riyadh recorded 46 new infections, Jeddah 18, Makkah 18, Dammam 14 and Yanbu 13.16 deaths were also recorded, bringing the total deaths to 5,796.

The Ministry always stresses the importance of adhering to the precautionary measures, a commitment to spacing, washing hands, and always wearing a muzzle while leaving the house and not tolerating it.

You also remember the steps to easily and easily receive the result of the corona test, which are: Download the Health app, book an appointment, go to the appointment and receive your results.

Active cases reached 5,877, of which 765 are critical.

Not yet. Many potential vaccines for COVID-19 are being studied, and several large clinical trials may report results later this year. If a vaccine is proven safe and effective, it must be approved by national regulators, manufactured to exacting standards, and distributed.

WHO is working with partners around the world to help coordinate key steps in this process. Once a safe and effective vaccine is available, WHO will work to facilitate equitable access for the billions of people who will need it.  

The vaccines must be proven safe and effective in large (phase III) clinical trials. Many potential vaccines for COVID-19 are being studied, and some of the large clinical trials may report results in late 2020 or early 2021.

A series of independent reviews of the efficacy and safety evidence is required, including regulatory review and approval in the country where the vaccine is manufactured, before WHO considers a vaccine product for prequalification. Part of this process also involves the Global Advisory Committee on Vaccine Safety.

An external panel of experts convened by WHO, called SAGE, will analyze the results from clinical trials and along with evidence on the disease, age groups affected, risk factors for disease, and other information, they will recommend whether and how the vaccines should be used. Officials in individual countries will decide whether to approve the vaccines for national use and develop policies for how to use the vaccines in their country based on the WHO recommendations.

The vaccines must be manufactured in large quantities, which will be a major and unprecedented challenge – all the while continuing to produce all the other important life-saving vaccines already in use.

As a final step, vaccines will be distributed through a complex logistical process, with rigorous stock management and temperature control.

WHO is working with partners around the world to accelerate every step of this process, while also ensuring the highest safety standards are met.

WHO is cautiously optimistic that safe and effective vaccines for COVID-19 will be successfully developed. There is a robust pipeline of potential vaccines in development, and some have already advanced to large (phase III) clinical trials based on promising early data.

But for now, we can’t be certain if or when a COVID-19 vaccine will be available. That is why we must not rely on a future vaccine to fight this pandemic – we must use all the tools we already have at our disposal, such as testing, contact tracing, physical distancing, and the use of masks.

Would a vaccine protect everyone?

People respond differently to immunisation.

History suggests any vaccine could be less successful in old people because an aged immune system does not respond as well, as happens with the annual flu jab. But data so far suggests this may not be a problem with some of Covid vaccines

Multiple doses may overcome any problems, as could giving it alongside a chemical (called an adjuvant) that boosts the immune system.

Short link :